Abstracts tagged "longitudinal studies"

Abstract Number: 1846 • ACR Convergence 2023
A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders
Titilayo Adeniran, Bertilia Trieu, Claudia Zurlini, Bonnie McGrath, Linda Roberts, Pamela Sanchez-Villagomez, Vilma Briones, Robyn Wiesel, Sandra Goldsmith and Laura Robbins, Hospital for Special Surgery, New York, NY
Background/Purpose: Musculoskeletal disorders are a leading cause of disability worldwide, with low back pain being one of the primary causes. The World Health Organization (WHO)…
Abstract Number: 1865 • ACR Convergence 2023
Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative
Daniel Chan Chun Kong¹, Philip Conaghan² and Mark Campbell³, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Leeds, Leeds, United Kingdom, ³Elisabeth Bruyere Hospital, Ottawa, ON, Canada
Background/Purpose: Knee flexion contracture (FC) is associated with worse clinical outcomes in those with knee OA. Cross sectional data demonstrated that knee FC was associated…
Abstract Number: 0104 • ACR Convergence 2023
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
Yin Long¹, Jiuliang zhao², Mengtao Li², Xinping Tian² and xiaofeng Zeng³, ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
Abstract Number: 1978 • ACR Convergence 2023
Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative
Kwanghoon Lee¹, Marina Banuls-Mirete², Alecio Lombardi³, Alexander Posis³, Eric Chang³, Nancy Lane⁴ and Monica Guma⁵, ¹Dongguk University ilsan Hospital, San Diego, CA, ²Department of Medicine, University of California San Diego, San Diego, CA, ³University of California San Diego, San Diego, CA, ⁴University of California, Hillsborough, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Adipose tissue is associated with knee osteoarthritis (KOA) progression. This study aimed to determine the association of infrapatellar fat pad (IPFP) size and subcutaneous…
Abstract Number: 0199 • ACR Convergence 2023
Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus
Laura Mas Sanchez¹, Pablo Francisco Muñoz Martínez², Elena Grau Garcia³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Marta De la Rubia Navarro¹, Ernesto Tovar Sugrañes³, Jose Ivorra Cortes³, Luis Gonzalez Puig³, Rosa Negueroles Albuixech³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Isabel Martinez Cordellat³, Hikmat Charia³, Ines Canovas Olmos³, Carmen Najera Herranz³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valéncia, Spain, ²Rheumatology Department. HUP La Fe, Sagunto, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Herpes zoster infection is due to the reactivation of the varicella-zoster virus (VZV), having a high prevalence in elderly and immunocompromised patients. Since the…
Abstract Number: 1979 • ACR Convergence 2023
Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis
Jie Wei¹, david Hunter², Nancy Lane³, Jing Wu⁴, Chao Zeng⁵, Guanghua Lei⁵ and Yuqing Zhang⁶, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³University of California, Hillsborough, CA, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: The current international guidelines recommend weight loss for pain relief and functional improvement in overweight or obese patients with knee or hip osteoarthritis; however,…
Abstract Number: 0546 • ACR Convergence 2023
Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis
Lu Liu, Karina de Leeuw, Suzanne Arends, Berber Doornbos-van der Meer, Harry van Goor and Johanna Westra, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Lupus nephritis (LN) is regarded as one of the most severe manifestations of systemic lupus erythematosus (SLE). This inflammation in the kidneys may lead…
Abstract Number: 2034 • ACR Convergence 2023
Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire
Ranjan Gupta¹, Rudra Prosad Goswami², Manshi Yadav¹, Sandhya Saini¹, Anju Mohan¹ and Vanamail Perumal¹, ¹All India Institute of Medical Sciences, New Delhi, India, ²Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients' knowledge, beliefs and perception about their disease which can help them in coping…
Abstract Number: 0810 • ACR Convergence 2023
Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The COVID-19 pandemic prompted a rapid transition to increased telehealth utilization, with many rheumatology providers replacing in-person clinical visits with telehealth visits or expanding…
Abstract Number: 2245 • ACR Convergence 2023
Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
Lars Erik¹, Kim A Papp², Andrew Östör³, Vassilis Stakias⁴, Tshepiso Madihlaba⁴, Ralph Lippe⁵, Ran Liu⁴ and Diamant Thaçi⁶, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ³Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…
Abstract Number: 1172 • ACR Convergence 2023
Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Hideaki Tsuji¹, Fabricio Espinosa-Ortega², Maryam Dastmalchi², Ingrid Lundberg² and Karin Lodin³, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden
Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
Abstract Number: 2325 • ACR Convergence 2023
Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Emily Littlejohn¹, Lingxuan Kong², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear antibodies (ANAs) are a hallmark of systemic lupus erythematosus (SLE) and also a marker of subclinical autoimmunity. While a seminal study using the…
Abstract Number: 0322 • ACR Convergence 2022
Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan², Carolina Munoz², Maria Carmela Tartaglia⁵, Leslet Ruttan⁶, Joan Wither⁷, May Choi⁸, Dennisse Bonilla², Nicole Anderson², Simone Appenzeller⁹, Ben Parker¹⁰, Patricia Katz¹¹, Dorcas Beaton¹², Robin Green⁶, Ian N. Bruce¹³ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Unicamp, Campinas, São Paulo, Brazil, ¹⁰Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹¹UCSF, San Rafael, CA, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Many in-person research studies, such as ours examining cognitive impairment (CI) in SLE, were paused for safety reasons during the COVID-19 pandemic. To restart…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].